- within Criminal Law topic(s)
Earlier this week, Shanghai Henlius Biotech, Inc. announced that it has entered into a semi-exclusive license agreement with Abbott Operations Uruguay S.R.L. for the commercialization of HANLIKANG (rituximab) and HANQUYOU (trastuzumab, trade name in Europe: Zercepac®), two products developed by Henlius, in Brazil. According to the announcement, Abbott will pay Henlius an up-front fee of $3 million (USD), and up to an aggregate of $1.4 million (USD) for certain regulatory milestone payments. Henlius states that the agreement "will help the company to further expand the overseas market of" the two products subject to the license.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
